Ellington Management Group LLC acquired a new position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,500 shares of the medical research company’s stock, valued at approximately $497,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC grew its stake in Charles River Laboratories Intl. by 6.7% in the fourth quarter. Geode Capital Management LLC now owns 457,529 shares of the medical research company’s stock valued at $51,782,000 after purchasing an additional 28,878 shares in the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Charles River Laboratories Intl. in the first quarter valued at approximately $244,000. Raymond James & Associates lifted its position in shares of Charles River Laboratories Intl. by 19.0% in the first quarter. Raymond James & Associates now owns 38,398 shares of the medical research company’s stock valued at $5,577,000 after buying an additional 6,133 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Charles River Laboratories Intl. by 4.2% in the first quarter. JPMorgan Chase & Co. now owns 85,850 shares of the medical research company’s stock valued at $12,470,000 after buying an additional 3,471 shares during the last quarter. Finally, Clark Capital Management Group Inc. lifted its position in shares of Charles River Laboratories Intl. by 3.0% in the first quarter. Clark Capital Management Group Inc. now owns 137,207 shares of the medical research company’s stock valued at $19,929,000 after buying an additional 3,979 shares during the last quarter. 94.31% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on CRL shares. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. SunTrust Banks raised their price objective on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research report on Monday. Leerink Swann started coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They issued an “outperform” rating for the company. Svb Leerink started coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They issued an “outperform” rating and a $155.00 price objective for the company. Finally, Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Monday, September 9th. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $149.23.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction on Monday, August 12th. The stock was sold at an average price of $130.36, for a total value of $162,819.64. Following the completion of the transaction, the insider now directly owns 19,327 shares of the company’s stock, valued at approximately $2,519,467.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.80% of the stock is owned by insiders.

NYSE:CRL opened at $133.77 on Wednesday. The stock has a market cap of $6.45 billion, a P/E ratio of 22.18, a PEG ratio of 1.69 and a beta of 1.09. The stock has a 50 day simple moving average of $131.29 and a 200 day simple moving average of $136.01. The company has a current ratio of 1.59, a quick ratio of 1.38 and a debt-to-equity ratio of 1.47. Charles River Laboratories Intl. Inc has a 1-year low of $103.00 and a 1-year high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.55 by $0.08. The business had revenue of $657.60 million during the quarter, compared to analysts’ expectations of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the firm posted $1.62 EPS. As a group, sell-side analysts forecast that Charles River Laboratories Intl. Inc will post 6.52 EPS for the current year.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: What Factors Can Affect Return on Equity?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.